Cardiovascular outcomes of SGLT2 inhibitors across the spectrum of myocardial infarction: A systematic review and meta-analysis.
AIMS Sodium-glucose cotransporter-2 inhibitors (SGLT2i) help in heart failure (HF), but their benefit after acute myocardial infarction is unclear. This meta-analysis assesses their impact on mortality and heart failure hospitalization post-acute myocardial infarction (AMI) and identifies which patients benefit most....